| Literature DB >> 34885770 |
Anna Nowak1, Wiktoria Duchnik2, Edyta Makuch3, Łukasz Kucharski1, Paula Ossowicz-Rupniewska3, Krystyna Cybulska4, Tadeusz Sulikowski5, Michał Moritz2, Adam Klimowicz1.
Abstract
Epilobium angustifolium L. is a popular medicinal plant found in many regions of the world. This plant contains small amounts of essential oil whose composition and properties have not been extensively investigated. There are few reports in the literature on the antioxidant and antifungal properties of this essential oil and the possibility of applying it as a potential promoter of the skin penetration of drugs. The essential oil was obtained by distillation using a Clavenger type apparatus. The chemical composition was analyzed by the GC-MS method. The major active compounds of E. angustifolium L. essential oil (EOEa) were terpenes, including α-caryophyllene oxide, eucalyptol, β-linalool, camphor, (S)-carvone, and β-caryophyllene. The analyzed essential oil was also characterized by antioxidant activity amounting to 78% RSA (Radical Scavenging Activity). Antifungal activity against the strains Aspergillus niger, A. ochraceus, A. parasiticum, and Penicillium cyclopium was also determined. The largest inhibition zone was observed for strains from the Aspergillus group. The EOEa enhanced the percutaneous penetration of ibuprofen and lidocaine. After a 24 h test, the content of terpene in the skin and the acceptor fluid was examined. It has been shown that the main compounds contained in the essential oil do not penetrate through the skin, but accumulate in it. Additionally, FTIR-ATR analysis showed a disturbance of the stratum corneum (SC) lipids caused by the essential oil application. Due to its rich composition and high biological activity, EOEa may be a potential candidate to be applied, for example, in the pharmaceutical or cosmetic industries. Moreover, due to the reaction of the essential oil components with SC lipids, the EOEa could be an effective permeation enhancer of topically applied hydrophilic and lipophilic drugs.Entities:
Keywords: Franz diffusion cell; antifungal activity; antioxidant activity; chemical composition; enhancement penetration; essential oil; fireweed
Mesh:
Substances:
Year: 2021 PMID: 34885770 PMCID: PMC8658823 DOI: 10.3390/molecules26237188
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Major components of E. angustifolium essential oil determined with gas chromatography-mass spectrometry (GC-MS). Mean (±standard deviation), n = 3.
| No. | Retention Time | Compound Name | Area |
|---|---|---|---|
| 1 | 9.57 | Eucalyptol | 3.20 ± 0.092 |
| 2 | 10.57 | β-Linalool | 4.54 ± 0.031 |
| 3 | 11.54 | Camphor | 3.90 ± 0.183 |
| 4 | 11.93 | (+)-Isomenthol | 2.42 ± 0.081 |
| 5 | 12.21 | α-Terpineol | 1.98 ± 0.072 |
| 6 | 12.96 | (S)-Carvone | 3.99 ± 0.132 |
| 7 | 13.49 | Thymol | 2.65 ± 0.177 |
| 8 | 13.55 | Anethole | 1.94 ± 0.095 |
| 9 | 13.65 | Carvacrol | 2.41 ± 0.202 |
| 10 | 14.39 | α-Terpinyl acetate | 0.53 ± 0.036 |
| 11 | 14.88 | δ-Cadinene | 0.61 ± 0.144 |
| 12 | 15.10 | Germacradien-4-ol | 1.67 ± 0.210 |
| 13 | 15.59 | β-Caryophyllene | 3.75 ± 0.234 |
| 14 | 16.23 | γ-Cadinene | 2.05 ± 0.094 |
| 15 | 16.75 | β-Cadinene | 2.11 ± 0.094 |
| 16 | 17.71 | α-Caryophyllene oxide | 8.57 ± 0.184 |
| 17 | 18.05 | α-Caryophyllene | 2.49 ± 0.397 |
| 18 | 18.35 | β-Caryophyllene oxide | 2.73 ± 0.091 |
| 19 | 18.50 | α-Cadinol | 2.60 ± 0.054 |
| 20 | 18.66 | β- Caryophyllene | 2.98 ± 0.489 |
| 21 | 19.94 | Secalciferol | 1.34 ± 0.099 |
| 20.09 | 1.35 ± 0.098 | ||
| 22 | 20.27 | Trimethylpentadecan-2-one | 0.54 ± 0.067 |
| 23 | 24.72 | 5-Methyldocosane | 14.95 ± 0.301 |
| 24 | 26.40 | Cosanes | 5.82 ± 0.304 |
| 27.52 | 6.75 ± 0.335 | ||
| 28.09 | 11.13 ± 0.779 |
Figure 1The structural formulas of the main terpenes identified in the E. angustifolium essential oil.
Antioxidant activity of E. angustifolium essential oil. Mean (±standard deviation), n = 3.
| Antioxidant Activity | |
|---|---|
| DPPH [mg Trolox/g EOEa] | 2.445 ± 0.025 |
| RSA [%] | 78.021 ± 0.755 |
The influence of E. angustifolium essential oil on inhibiting of the growth of selected mold fungi (mean ± SD of the diameter of the growth inhibition zone in mm), EOEa—E. angustifolium essential oil.
| Fungi | Concentration of EOEa | |||
|---|---|---|---|---|
| 12.5 | 25 | 50 | 100 | |
|
| 10.10 ± 1.00 a | 13.90 ± 1.80 b | 15.30 ± 1.50 c | 21.00 ± 2.20 d |
|
| 12.15 ± 1.50 a | 15.00 ± 1.50 ab | 19.10 ± 2.00 c | 28.30 ± 3.90 d |
|
| 9.00 ± 1.00 a | 12.45 ± 1.80 ab | 17.00 ± 2.60 c | 23.10 ± 2.60 d |
|
| 7.80 ± 1.70 a | 9.00 ± 1.30 b | 10.00 ± 2.50 b | 17.10 ± 2.00 c |
Different letters mean significant differences between individual concentrations, n = 3; the analysis was performed with a one-way analysis of variance (ANOVA, Tukey’s test, α = 0.05).
Skin permeation parameters for ibuprofen, lidocaine, and caffeine from emulsions with and without the E. angustifolium essential oil.
| Compound | JSS, µg/cm2∙h | KP∙103, cm/h | LT, h | D∙104, cm2/h | Km | Q%24h |
|---|---|---|---|---|---|---|
| CON-IBU | 26.238 ± 1.104 a | 2.624 ± 0.110 a | 1.795 ± 0.306 a | 2.321 ± 0.032 a | 0.565 ± 0.132 a | 2.17 ± 0.218 a |
| EOEa-IBU | 35.162 ± 1.152 b | 3.414 ± 0.111 b | 1.762 ± 0.195 a | 2.365 ± 0.019 a | 0.722 ± 0.062 b | 2.87 ± 0.176 a |
| CON-CAF | 16.267 ± 0.397 a | 1.611 ± 0.039 a | 1.571 ± 0.077 b | 2.652 ± 0.013 a | 0.304 ± 0.008 a | 1.91 ± 0.124 a |
| EOEa-CAF | 15.507 ± 3.532 a | 1.520 ± 0.346 a | 1.262 ± 0.436 a | 3.302 ± 0.174 b | 0.230 ± 0.120 a | 1.95 ± 0.200 a |
| CON-LID | 35.578 ± 0.732 a | 3.454 ± 0.071 a | 2.508 ± 0.037 a | 1.662 ± 0.024 a | 1.039 ± 0.006 a | 4.02 ± 0.685 a |
| EOEa-LID | 41.439 ± 0.239 b | 3.985 ± 0.022 a | 2.479 ± 0.064 a | 1.681 ± 0.046 a | 1.185 ± 0.025 a | 4.93 ± 0.353 b |
Jss—steady-state flux; KP—permeability coefficient; LT—lag time; D—diffusion coefficient; Km—skin partition coefficient; Q—the percentage of applied dose. EOEa-IBU—emulsion containing the E. angustifolium essential oil and ibuprofen; EOEa-LID—emulsion containing the E. angustifolium essential oil and lidocaine; EOEa-CAF—emulsion containing the E. angustifolium oil and caffeine; CON-IBU—emulsion containing only ibuprofen without the E. angustifolium essential oil; CON-LID—emulsion containing only lidocaine without the E. angustifolium essential oil; CON-CAF—emulsion containing only caffeine without the E. angustifolium essential oil. Different letters as ’a’ and ’b’ mean significant differences between individual emulsions (ANOVA, Tukey’s test, α = 0.05); the mean ± standard deviation SD (n = 3).
Figure 2The cumulative mass of ibuprofen in the acceptor fluid (A) and the penetration rate (B) of ibuprofen through the skin during the 24 h experiment, EOEa-IBU—emulsion containing the E. angustifolium essential oil, CON-IBU—control—an emulsion without the E. angustifolium essential oil. Each point and bar represents the mean ± standard deviation SD (n = 3). For * p < 0.0001 versus the control.
Figure 3The cumulative mass of lidocaine in the acceptor fluid (A) and the penetration rate (B) of lidocaine through the skin during the 24 h experiment, EOEa-LID—emulsion containing the E. angustifolium essential oil, CON-LID—control—an emulsion without the E. angustifolium essential oil. Each point and bar represents the mean ± standard deviation SD (n = 3). For * p < 0.0001 versus the control.
Figure 4The cumulative mass of caffeine in the acceptor fluid (A) and the penetration rate (B) of caffeine through the skin during the 24-h experiment, EOEa-CAF—emulsion containing the E. angustifolium essential oil, CON-CAF—control—an emulsion without the E. angustifolium essential oil. Each point and bar represents the mean ± standard deviation SD (n = 3). n.s.—no significant differences.
Figure 5GC-MS chromatogram of the samples after skin extraction after 24 h of penetration of emulsion contained the EOEa (a, black line) and of the acceptor fluid after 24 h of penetration of emulsion contained the EOEa (b, green line), RT—retention time (min).
Figure 6FTIR spectra of pig skin before and after 24 h treatment: (a) control sample, (b) E. angustifolium essential oil (EOEa), (c) the skin treated with E. angustifolium essential oil (EOEa).
Composition of emulsions used in pig skin penetration tests.
| Ingredient | EOEa–IBU | CON–IBU | EOEa–LID | CON–LID | EOEa–CAF | CON–CAF |
|---|---|---|---|---|---|---|
| EOEa * | 0.1 | - | 0.1 | - | 0.1 | - |
| IBU * | 0.1 | 0.1 | - | - | - | - |
| LID * | - | - | 0.1 | 0.1 | - | - |
| CAFF * | - | - | - | - | 0.1 | 0.1 |
| Propylene glycol * | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 |
| Biobase * | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 | 0.6 |
| Grape seed oil * | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 | 0.20 |
| Beeswax * | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 |
| Water up to * | 10 | 10 | 10 | 10 | 10 | 10 |
* The amount of components is expressed in g; EOEa—E. angustifolium essential oil. IBU—ibuprofen, LID—lidocaine, CAF—caffeine.